Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Nuclear Science and Technology (2)
- Biology and Environment (10)
- Clean Energy (17)
- Computational Engineering (1)
- Computer Science (1)
- Fusion and Fission (4)
- Isotope Development and Production (1)
- Isotopes (2)
- Materials (38)
- Materials Characterization (1)
- Materials for Computing (6)
- Materials Under Extremes (1)
- National Security (6)
- Neutron Science (19)
- Sensors and Controls (1)
- Supercomputing (24)
News Type
News Topics
- (-) Biomedical (1)
- (-) Materials Science (1)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (2)
- Bioenergy (1)
- Computer Science (1)
- Decarbonization (1)
- Fusion (1)
- Isotopes (2)
- Neutron Science (1)
- Nuclear Energy (7)
- Physics (1)
- Space Exploration (2)
- Sustainable Energy (1)
- Transformational Challenge Reactor (1)
Media Contacts
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
With the production of 50 grams of plutonium-238, researchers at the Department of Energy’s Oak Ridge National Laboratory have restored a U.S. capability dormant for nearly 30 years and set the course to provide power for NASA and other missions.